A simple model that suggests possible cost savings when modified-release prednisone 5 mg/day is added to current treatment in patients with active rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 52, Issue 8, 2013, Pages 1435-1437

  Boers, Maarten ^a   Buttgereit, Frank ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cost of treatment; Economic model; Glucocorticoids; Rheumatoid arthritis; Treatment

Indexed keywords

ANTIRHEUMATIC AGENT; PREDNISONE;

ARTICLE; BELGIUM; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DRUG COST; DRUG INDICATION; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REIMBURSEMENT; RHEUMATOID ARTHRITIS; UNITED KINGDOM;

COST OF TREATMENT; ECONOMIC MODEL; GLUCOCORTICOIDS; RHEUMATOID ARTHRITIS; TREATMENT;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BELGIUM; COST SAVINGS; COST-BENEFIT ANALYSIS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PREDNISONE;

EID: 84880635459     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket145     Document Type: Article

References (10)

1. Smolen JS, Aletaha D, Bijlsma JW et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
2. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
3. Bijlsma JW, Boers M, Saag KG et al. Glucocorticoids in the treatment of early and late RA. Ann Rheum Dis 2003; 62:1033-7.
4. Buttgereit F, Mehta DP, Kirwan J et al. Low-dose glucocorticoid chronotherapy of rheumatoid arthritis: a randomized clinical trial. Ann Rheum Dis 2013;72:204-10.
5. Hafstrom I, Albertsson K, Boonen A et al. Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study. Ann Rheum Dis 2009;68: 508-13.
6. Klarenbeek NB, Guler-Yuksel M, van der Kooij SM et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 2011;70: 1039-46.
7. van Tuyl LH, Boers M, Lems WF et al. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis 2010;69:807-12.
8. Bakker MF, Jacobs JW, Welsing PM et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012;156:329-39.
9. Buttgereit F, Doering G, Schaeffler A et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 2008;371:205-14.
10. Buttgereit F, Döring G, Knauer C et al. Chronotherapy of rheumatoid arthritis: CAPRA-1 demonstrates sustained efficacy of modified-release prednisone over 12 months. Ann Rheum Dis 2010;69(Suppl 3):21.